This Looks Like the Perfect Stock for Warren Buffett and Greg Abel to Buy Right Now

McCormick is set to acquire Unilever’s food business in a deal that would roughly double its size and require about $16B of cash raising. The market initially reacted negatively as the stock fell ~15% on deal scope, but the article highlights a historically high 3.7% yield and low ~9x P/E as valuation support. Berkshire Hathaway CEO Greg Abel is described as having enough cash (nearly $400B) to fund/benefit from the broader M&A opportunity, contrasting this with the cost-cutting failure of the Kraft Heinz merger.

Analysis

This is less a story about merger synergies than about whether a premium branded-food platform can actually earn its cost of capital after scale expansion. MKC is the only entity here with a plausible path to moat expansion, but the market is correctly pricing the execution gap: if integration forces heavier trade-spend and working-capital drag, the headline accretion will be offset by lower organic growth and a lower terminal multiple. UL is the cleaner capital-allocation winner because it can de-risk the portfolio and recycle proceeds into categories with better return on invested capital; KHC remains the cautionary reference point for what happens when staples M&A becomes a leverage-and-cut story instead of a brand-investment story.

The near-term driver is financing structure, not strategy. A preferred-style solution would be the most equity-friendly outcome for MKC and could give BRK a high-carry, low-durability-risk instrument, but that only matters if it avoids expensive common equity or leverage that leaves the company stuck above its comfort range. Over the next 1-3 months, the market will trade the pro forma leverage ratio, synergy credibility, and management’s willingness to protect brand spend; if they cannot outline a credible path to delevering below roughly 4x EBITDA within 24 months, the stock likely de-rates further.

The consensus is still too focused on the KHC merger analogy and not enough on private-label pressure and retailer bargaining power, which can quietly erode pricing power for years. Over 6-18 months, the real falsifier is volume stability: if MKC can hold share while expanding the portfolio, the multiple can recover; if not, this becomes a slow-growth balance-sheet story. A cleaner financing package or a strong pro forma FCF guide would reverse the current skepticism; a dividend reset, equity issuance, or leverage above ~5x would validate the bear case.

Key Decisions for Investors

• MKC: stay on the sidelines until financing terms are public; only consider a starter long if the deal is funded without equity dilution and pro forma leverage is <4x EBITDA. Risk/reward is asymmetric only if the market is mispricing integration, not if it is underpricing financing risk.
• Pair trade over 3-6 months: long UL / short KHC. UL benefits from capital recycling and portfolio simplification, while KHC remains the clearest symbol of value destruction when staples scale is not matched by innovation. Cover the short if KHC announces meaningful asset sales, buybacks, or a credible restructuring path.
• BRK.B: if Berkshire takes preferred paper, treat it as a small, low-volatility income opportunity rather than a high-conviction equity catalyst. The upside is modest but the downside is limited; abandon the idea if Berkshire passes, which would suggest the underwriting is less attractive than advertised.
• Do not use options on MKC before the financing structure is disclosed. If the stock rallies on vague deal enthusiasm, fade the move only after terms confirm expensive debt or dilution; if terms are clean, reassess for a rerating trade.